Oncology R&D: the patient insights we’re still missing, and how to catch upImagine you are a pharma executive working in oncology R&D. The landscape is rapidly becoming more competitive and Share XOncology R&D: the patient insights we’re still missing, and how to catch uphttps://deep-dive.pharmaphorum.com/magazine/oncology-2021/oncology-rd-patient-engagement/
Why relationships are key in rare disease patient engagementReal-world data is a vital part of rare disease drug development, but to get a true picture of Share XWhy relationships are key in rare disease patient engagementhttps://pharmaphorum.com/views-and-analysis/why-relationships-are-key-in-rare-disease-patient-engagement/
Deep Dive: Market AccessIt’s fair to say this is the most interesting time ever for market access. Not only has COVID Share XDeep Dive: Market Accesshttps://pharmaphorum.com/views-analysis-market-access/deep-dive-market-access-2021/
Patient involvement in trial design: looking to the futureCOVID-19 has transformed the way we think about patient participation in trial design – but there are still Share XPatient involvement in trial design: looking to the futurehttps://pharmaphorum.com/patients/patient-involvement-in-trial-design-looking-to-the-future/
Deep Dive: Patients and PartnershipsAs this issue’s title suggests, patient centricity is about more than just talking points and marketing strategies – Share XDeep Dive: Patients and Partnershipshttps://pharmaphorum.com/views-analysis-patients/deep-dive-patients-and-partnerships/
3 steps for comprehensive patient collaborationJanssen’s Daniel de Schryver tells us why it’s time to give patients a permanent seat at the table Share X3 steps for comprehensive patient collaborationhttps://pharmaphorum.com/views-analysis-patients/3-steps-for-comprehensive-patient-collaboration/
Increasing patient engagement with UK clinical trialsPharmaceutical companies often struggle to actively involve patients in the design phase of clinical trials but doing so Share XIncreasing patient engagement with UK clinical trialshttps://pharmaphorum.com/webinars/uk-regulatory-pathway-patient-engagement-trials/
Are rapid progress and patient engagement mutually exclusive in a COVID-19 world?COVID-19 has sparked a flurry of research and discoveries are being made at an unprecedented rate – but Share XAre rapid progress and patient engagement mutually exclusive in a COVID-19 world?https://pharmaphorum.com/r-d/views-analysis-r-d/are-rapid-progress-and-patient-engagement-mutually-exclusive-in-a-covid-19-world/
Working with, advocating for, and empowering patients – a holistic viewIn recent years, there has been a clear shift in pharma when it comes to how it interacts Share XWorking with, advocating for, and empowering patients – a holistic viewhttps://pharmaphorum.com/views-analysis-patients/working-advocating-empowering-patient-centricity/
